Emicizumab
Generic name
Emicizumab
Brand name
ATC Code
B02BX06
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Pharmacokinetic parameters in children are similar to adults
| Vd | 0,15 l/kg |
| T1/2 | Approx. 28 days |
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The safety profile in babies, infants, children and adolescents is similar to the adult profile.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Be careful in children < 1 years of age as the hemostatic system is still immature. The relative concentrations of pro- and anticoagulation proteins and the potential risk of trombosis should be taken into account in this age group.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
VITAMIN K AND OTHER HEMOSTATICS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Vitamin K | ||
|---|---|---|
| B02BA01 | ||
| Fibrinogen | ||
|---|---|---|
| B02BB01 | ||
| Local hemostatics | ||
|---|---|---|
| B02BC30 | ||
| Blood coagulation factors | ||
|---|---|---|
| B02BD08 | ||
| B02BD04 | ||
| B02BD02 | ||
| B02BD01 | ||
| Other systemic hemostatics | ||
|---|---|---|
| B02BX05 | ||
| B02BX04 | ||
| Blood coagulation factors | ||
|---|---|---|
| B02BD08 | ||
| B02BD04 | ||
| B02BD02 | ||
| B02BD01 | ||
Reference
- Roche Registration GmbH, SmPC Hemlibra (EU/1/18/1271/001-004) 05-06-2019, www.ema.europa.eu/en/medicines/human
Changes
Therapeutic Drug Monitoring
Overdose
